Figure 5.

Survival benefit after MCMV IT therapy depends on CD8⁺ T-cells. Mice were depleted of CD8⁺ and/or NK1.1⁺ cells as described in the materials and methods (n = 8 mice per group) or the relevant isotype control antibodies (n = 6 mice per group). (a) Tumor growth, represented as change in tumor area (mm²) over time, is shown from the day of the first intratumoral (IT) injection. (b) Kaplan Meier survival curves of the different antibody depletion groups compared to the relevant isotype controls from day of tumor implantation until tumors were above 100 mm². Significance was assessed by a logrank test, *P < 0.05. CMV, cytomegalovirus; MCMV, vaccination with murine-CMV.